Immune Changes in “Hepatitis Inflammation and Cancer Transformation Process” from the Perspective of Traditional Chinese Medicine
DOI:
https://doi.org/10.53469/jcmp.2024.06(07).08Keywords:
Chronic hepatitis, Inflammatory-cancer transformation, Yin-yang balance, Immune balanceAbstract
Yin-yang harmony is the core idea of Chinese medicine theory, which has important guiding significance in the prevention and treatment of chronic hepatitis "inflammation and cancer Transformation". Modern medicine believes that the change of immune response is one of the reasons affecting tumorigenesis, and intervening the immune response through drugs is the most promising means of cancer treatment for human beings. The yin and yang, collaterals and qi and blood doctrines of Chinese medicine are compatible with the understanding of modern medicine on immunity, especially the concept of replacing "immune-enhancing therapy" with "immune-normalizing therapy", which is consistent with "yin and yang harmonization" to restore the body's vitality. In particular, the concept of "immune normalization therapy" instead of "immune enhancement therapy" has been proposed in recent years, which is consistent with the core idea of "yin and yang harmony" in Chinese medicine to restore the relative balance of the body. This paper discusses the complementary nature of Chinese and Western medicine, with the intention of promoting the development of traditional and modern medicine in the process of preventing and treating "inflammation and cancer transformation" in chronic interventions.
References
Iñarrairaegui M, Melero I, Sangro B. Immunotherapy of Hepatocellular Carcinoma: Facts and HopesImmunotherapy of HCC[J]. Clinical Cancer Research, 2018, 24(7): 1518-1524.
Li Nan. Discussion on the mechanism of neuroendocrine immune network and emotional pathogenesis[J]. Research on Traditional Chinese Medicine, 2008(03):3-5.
YANG Tiantian, ZHONG Yitong, WU Wanyin, YANG Xiaobing. Exploring the balance of yin and yang in Chinese medicine and tumor immunity based on the immune editing hypothesis[J]. Journal of TCM Oncology, 2022, 4(04):30-36.DOI:10.19811/j.cnki.ISSN2096-6628.2022.07.006.
Guixian Zhang, Hongbin Liu, David Liu. Study on the correlation between non-controllable inflammation and tumor[J]. Chinese Journal of Integrative Surgery, 2015, 21(02):197-201.
XIAN Linfeng, FANG Letian, LIU Wenbin, ZHAO Pei, CHEN Yifan, CAO Guangwen. Current status of primary liver cancer, main pathogenesis, prevention and control strategies[J]. China Cancer Prevention and Control Magazine, 2022, 14(03):320-328.
YANG Qiaoli, ZHENG Haofei, LIU Ying. Discussion on the therapeutic effect of warming kidney yang on human immunocompromise[J]. Shizhen Guomao Guomao, 2017, 28(04):919-920.
XIE Shiping, WU Xingwei, XU Qianlei, SAN Haiyan, MA Suna, WANG Juan, LIU Sa, LU Shunwu. "Spleen is the guardian" on the treatment of AIDS[J]. Chinese Journal of Traditional Chinese Medicine, 2013, 28(07):1936-1939.
LI Jing, ZHAO Liangchen, TANG Xinglinzi, FANG Cantu, ZHONG Juanna, CHEN Ting. Relationship between "Wei qi" of traditional Chinese medicine and modern immune regulation and tumorigenesis[J]. Journal of Traditional Chinese Medicine and Oncology[J]. Journal of Chinese Medicine Tumor, 2019, 1(02):18-22.DOI:10.19811/j.cnki.issn2096-6628.2019.02.006.
Yang JK, Feng QS. Analyzing the theory of "the liver is in charge of waiting outside" and its clinical application[J]. China Journal of Basic Chinese Medicine, 2015, 21(11):1350-1351.DOI:10.19945/j.cnki.issn.1006-3250.2015.11.007.
ZHAO Zhongwei, WANG Jiwei, WANG Wei. Discussion on the theory of hepatocellular carcinoma toxic ambulatory liver complex[J]. Shizhen Guojian Guojian, 2021, 32(12):2968-2969.
SHI Lei, MA Jizheng, LIU Shaoneng. The application of the theory of lorem ipsum in the study of liver fibrosis[J]. Chinese Traditional Medicine Science and Technology, 2010, 17(06):559-560.
CHENG Zi-wei, CHENG Wei, XING Dongwei, ZHANG Minguang. Asparagus polysaccharide synergizes with HIF1αRNAi to inhibit angiogenesis in hepatocellular carcinoma under hypoxic environment[J]. Shizhen Guomian Guomian Medicine, 2020, 31(12):2817-2820.
Jain R K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy[J]. Science, 2005, 307(5706): 58-62.
HAN Tongwei. "Balanced blockade therapy gives a new light to life--Interview with Feng Li, Director of Oncology Department of Wangjing Hospital[J]. China Contemporary Medicine, 2009, 16(17):2.
Sanmamed M F, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization[J]. Cell, 2018, 175(2): 313-326.
Buchbinder E I, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition[J]. American journal of clinical oncology, 2016, 39(1): 98.
Freeman G J, Long A J, Iwai Y, et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation[J]. Journal of Experimental Medicine, 2000, 192(7): 1027-1034.
Spranger S, Spaapen R M, Zha Y, et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells[J]. Science translational medicine, 2013, 5(200): 200ra116-200ra116.
Alsaab H O, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome[J]. Frontiers in pharmacology, 2017, 8: 561.
LIU Qinghua, WANG Lulu. Theoretical discussion on tumor immunotherapy based on the relationship between positive and evil doctrines in Chinese medicine[J]. Journal of TCM Oncology, 2019(01):8-11. DOI:10.19811/j.cnki.issn2096-6628.2019.01.003.
Li Yuan, Zhao Ying, Chen Meng, Lin Jie, Li Tao, Zhang Jianglan, Chu Fuhao, Zou Haojing, Su Zeqi, Ding Xia. Immune imbalance and reconstruction in the process of "inflammation-cancer transformation" in chronic gastritis from the perspective of Chinese medicine[J]. Journal of Beijing University of Chinese Medicine, 2021, 44(01):92-96.
SONG Lei, ZHANG Lan, TANG Min, LI Deyun, YANG Guimin, YAO Shengfang, LIU Yawei. The use of Chinese medicine in integrative medicine therapy for malignant tumors[J]. Journal of Chinese Medicine, 2018, 33(05):712-715.DOI:10.16368/j.issn.1674-8999.2018.05.170.
YU Fengming, ZHENG Chuan, YU Haiyan, HU Yonghe, YAO Dejiao, WU Jie. The theory of meridian attribution in Chinese medicine, meridian-inducing drugs and tumor-targeted drug therapy[J]. Shizhen Guomao Guomao, 2015, 26(05):1185-1186.
CHENG ZHEN, ZOU Liang, HU Yibing, PENG Xianxin, MA Yubiao, ZHAO Gang. Research progress on the theory of Chinese medicinal drug citation and drug targeting[J]. Chinese Journal of Experimental Formulas, 2011, 17(13):277-280.DOI:10.13422/j.cnki.syfjx.2011.13.081.
Yang Shulan. Establishment of a model of hepatitis B in congenitally infected South China ducks and verification of the effect of liver meridian-inducing drugs on the efficacy of 3TC anti-hepatitis B virus[D]. Guangzhou University of Traditional Chinese Medicine, 2001.
ZHI Yu-Xing, LI Hong-Mei, XU An-Long. Re-conceptualization of immunity from the perspective of Chinese and Western medicine--discussion based on evidence-based treatment and immune state[J]. Journal of Chinese Medicine, 2022, 63(21):2001-2008. DOI:10.13288/j.11-2166/r.2022.21.001.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jianjun Zhu, Xiaoquan Du
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
